Get the full picture
Sign in to uncover key details.
Show More
EpiBiologics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1900 Alameda de las Pulgas Ste 250, San ...Website
www.epibiologics.comRevenue
$11 MillionIndustry
About EpiBiologics
EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. EpiBiologics was founded on pioneering work from scientific founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Companys proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving extracellular proteins in a tissue-specific manner. EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology and immunology.Explore more
EpiBiologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to EpiBiologics
Compare insights from companies similar to EpiBiologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
EpiBiologics Tech Stack
A closer look at the technologies used by EpiBiologics
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EpiBiologics
Sign Up For FreeTo access detailed company insights
EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. EpiBiologics was founded on pioneering work from scientific founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Companys proprietary EpiTAC platform is a modular bispecific anti... Read More
